Golestan University of Medical Sciences Repository

A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment

Azizmohammadi, Z. and Tabei, F. and Shafiei, B. and Babaei, A.A. and Jukandan, S.M.Q. and Naghshine, R. and Javadi, H. and Nabipour, I. and Assadi, M. and Asli, I.N. (2013) A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment. Hellenic Journal of Nuclear Medicine, 16 (2). pp. 103-106. ISSN 17905427 (ISSN)

[img]
Preview
PDF - Published Version
Download (323kB) | Preview

Abstract

The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate hospital discharge planning in relation to three different sets of regulations. We studied 100 patients, 78 females and 22 males, aged 13 to 79 years (mean 44.40±15.83 years) with DTC, in three Groups who were treated with 3.7, 5.5 or 7.4GBq of 131I, respectively. The external whole-body dose rates following oral administration of 131I were measured after each one of the first three hospitalization days. A multivariant linear analysis was performed, considering exposure rates as dependent variables to the administered dose for treatment, age, gender, regional and/or distant metastases, thyroglobulin (Tg), antibodies to Tg and thyroid remnant in the three dose groups. We found that the exposure rates after each of the three first days of hospitalization were 30, 50 and 70μSvh-1 at 1m. All our DTC patients had an acceptable dose rate on days 2 and 3 that allowed their hospital discharge. After only 1 day of hospitalization, just 3/11 cases showed not permissible exposure rates above 70μSvh-1. In conclusion, it is the opinion of the authors that after measuring the exposure rates, most treated, DTC patients could be discharged after only one day of hospitalization, even some of those treated with high doses of 131I (7.4GBq). Patients, who received the higher doses of 131I, should not be released before their individual exposure rate is measured.

Item Type: Article
Additional Information: Unmapped bibliographic data: LA - English [Field not mapped to EPrints] J2 - Hell. J. Nucl. Med. [Field not mapped to EPrints] C2 - 23687641 [Field not mapped to EPrints] AD - Department of Nuclear Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran [Field not mapped to EPrints] AD - Department of Medical Physics and Engineering, Shahid Beheshti University of Medical Sciences, Tehran, Iran [Field not mapped to EPrints] AD - Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences (GUOMS), Gorgan, Iran [Field not mapped to EPrints] AD - Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 3631, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: Differentiated thyroid carcinoma, External dose rate, Hospital discharge, Radioiodine treatment, antibody, iodine 131, thyroglobulin, radioactive iodine, radiopharmaceutical agent, radioactive iodine, ablation therapy, adolescent, adult, aged, article, cancer patient, differentiated thyroid cancer, distant metastasis, drug megadose, female, hospital discharge, hospitalization, human, major clinical study, male, middle aged, radiation dose, radiation exposure, thyroid gland, thyroid remnant ablation treatment, young adult, body burden, clinical trial, Iran, minimal residual disease, prevalence, radiation dose, risk factor, statistics, thyroid tumor, treatment outcome, hospital discharge, Iran, statistics and numerical data, Thyroid Neoplasms, Adolescent, Adult, Aged, Body Burden, Female, Humans, Iodine Radioisotopes, Iran, Male, Middle Aged, Neoplasm, Residual, Patient Discharge, Prevalence, Radiation Dosage, Radiopharmaceuticals, Risk Factors, Thyroid Neoplasms, Treatment Outcome, Young Adult, Adolescent, Adult, Aged, Body Burden, Female, Humans, Iodine Radioisotopes, Iran, Male, Middle Aged, Neoplasm, Residual, Patient Discharge, Prevalence, Radiation Dosage, Radiopharmaceuticals, Risk Factors, Thyroid Neoplasms, Treatment Outcome, Young Adult
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 18 Apr 2015 04:42
Last Modified: 10 May 2015 04:21
URI: http://eprints.goums.ac.ir/id/eprint/1924

Actions (login required)

View Item View Item